General Information of Drug (ID: DMXLT8C)

Drug Name
Sulfisoxazole
Synonyms
Accuzole; Alphazole; Amidoxal; Astrazolo; Azosulfizin; Bactesulf; Barazae; Chemouag; Cosoxazole; Dorsulfan; ERYZOLE; Entusil; Entusul; Ganda; Gantrisin; Gantrisine; Gantrisona; Gantrosan; Isoxamin; Neazolin; Neoxazoi; Neoxazol; Novazolo; Novosaxazole; Pancid; Renosulfan; Resoxol; Roxosul; Roxoxol; SOXO; Saxosozine; Sodizole; Solfafurazolo; Sosol; Soxamide; Soxazole; Soxisol; Soxitabs; Soxomide; Stansin; Sulbio; Sulfadimethylisoxazole; Sulfafurazol; Sulfafurazole; Sulfafurazolum; Sulfagan; Sulfagen; Sulfaisoxazole; Sulfalar; Sulfapolar; Sulfasol; Sulfasoxazole; Sulfasoxizole; Sulfazin; Sulfisin; Sulfisonazole; Sulfisoxasole; Sulfisoxazol; Sulfisoxazolum; Sulfizin; Sulfizol; Sulfizole; Sulfofurazole; Sulfoxol; Suloxsol; Sulphadimethylisoxazole; Sulphafuraz; Sulphafurazol; Sulphafurazole; Sulphafurazolum; Sulphaisoxazole; Sulphisoxazol; Sulphisoxazole; Sulphofurazole; Sulsoxin; Thiasin; Unisulf; Urisoxin; Uritrisin; Urogan; Vagilia; Azo Gantrisin; Component of Azo Gantrisin; Component of Azo Gantrisin Accuzole; Dorsulfan warthausen; Roxosul tablets; Solfafurazolo [DCIT]; Sulfafuraz ole; Sulfisoxazole [USAN]; Sulfisoxazole dialamine; NU 445; Component of Azo-Sulfizin; G-sox; Gantrisin (TN); J-Sul; Koro-sulf; Norilgan-S; SK-Soxazole; Sulfafurazole (INN); Sulfafurazolum [INN-Latin]; Sulfazin (VAN); Sulfisoxazole-Carc; Tl-azole; US-67; V-Sul; Sulfisoxazole (JP15/USP); U.S.-67; 3,4-Dimethyl-5-sulfanilamidoisoxazole; 3,4-Dimethyl-5-sulfonamidoisoxazole; 3,4-Dimethyl-5-sulphanilamidoisoxazole; 3,4-Dimethyl-5-sulphonamidoisoxazole; 3,4-Dimethylisoxale-5-sulfanilamide; 3,4-Dimethylisoxazole-5-sulfanilamide; 3,4-Dimethylisoxazole-5-sulphanilamide; 3,4-dimethylisoaxazole-5-sulfanilimide; 5-Sulfanilamido-3,4-dimethyl-isoxazole; 5-Sulfanilamido-3,4-dimethylisoxazole; 5-Sulphanilamido-3,4-dimethyl-isoxazole
Indication
Disease Entry ICD 11 Status REF
Acute otitis media AB00 Approved [1]
Chancroid N.A. Approved [1]
Inclusion conjunctivitis N.A. Approved [1]
Meningococcal meningitis N.A. Approved [1]
Plasmodium falciparum malaria 1F40 Approved [1]
Trachoma N.A. Approved [1]
Urinary tract infection GC08 Approved [2]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Antiinfective Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 267.31
Logarithm of the Partition Coefficient (xlogp) 1
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 4: low solubility and low permeability [3]
Bioavailability
96% of drug becomes completely available to its intended biological destination(s) [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 0.3 mL/min/kg [5]
Elimination
49% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 7.4 hours [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 249.52437 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.079% [5]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.17 L/kg [5]
Water Solubility
The ability of drug to dissolve in water is measured as 0.13 mg/mL [3]
Chemical Identifiers
Formula
C11H13N3O3S
IUPAC Name
4-amino-N-(3,4-dimethyl-1,2-oxazol-5-yl)benzenesulfonamide
Canonical SMILES
CC1=C(ON=C1C)NS(=O)(=O)C2=CC=C(C=C2)N
InChI
InChI=1S/C11H13N3O3S/c1-7-8(2)13-17-11(7)14-18(15,16)10-5-3-9(12)4-6-10/h3-6,14H,12H2,1-2H3
InChIKey
NHUHCSRWZMLRLA-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5344
ChEBI ID
CHEBI:102484
CAS Number
127-69-5
DrugBank ID
DB00263
TTD ID
D09TBD
INTEDE ID
DR1510
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial Dihydropteroate synthetase (Bact folP) TT4ILYC DHPS_ECOLI Inhibitor [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2C9 (CYP2C9)
Main DME
DE5IED8 CP2C9_HUMAN Substrate [8]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Gene/Protein Processing [9]
Serum paraoxonase/arylesterase 1 (PON1) OTD0Z2XO PON1_HUMAN Gene/Protein Processing [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Sulfisoxazole (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Sulfisoxazole and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [11]
Repaglinide DM5SXUV Moderate Increased risk of hypoglycemia by the combination of Sulfisoxazole and Repaglinide. Acute diabete complication [5A2Y] [12]
Glibenclamide DM8JXPZ Moderate Increased risk of hypoglycemia by the combination of Sulfisoxazole and Glibenclamide. Acute diabete complication [5A2Y] [12]
Tolazamide DMIHRNA Moderate Increased risk of hypoglycemia by the combination of Sulfisoxazole and Tolazamide. Acute diabete complication [5A2Y] [13]
Nateglinide DMLK2QH Moderate Increased risk of hypoglycemia by the combination of Sulfisoxazole and Nateglinide. Acute diabete complication [5A2Y] [12]
Insulin-glulisine DMQI0FU Moderate Increased risk of hypoglycemia by the combination of Sulfisoxazole and Insulin-glulisine. Acute diabete complication [5A2Y] [12]
Acetohexamide DMR6N7H Moderate Increased risk of hypoglycemia by the combination of Sulfisoxazole and Acetohexamide. Acute diabete complication [5A2Y] [13]
Insulin-aspart DMX7V28 Moderate Increased risk of hypoglycemia by the combination of Sulfisoxazole and Insulin-aspart. Acute diabete complication [5A2Y] [14]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Sulfisoxazole and Glipizide. Acute diabete complication [5A2Y] [12]
Thioguanine DM7NKEV Moderate Increased risk of hepatotoxicity by the combination of Sulfisoxazole and Thioguanine. Acute myeloid leukaemia [2A60] [15]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Sulfisoxazole and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [16]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Sulfisoxazole and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [17]
Mycophenolic acid DMRBMAU Moderate Altered absorption of Sulfisoxazole due to GI flora changes caused by Mycophenolic acid. Crohn disease [DD70] [18]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Sulfisoxazole and Cannabidiol. Epileptic encephalopathy [8A62] [19]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Sulfisoxazole and Brentuximab vedotin. Hodgkin lymphoma [2B30] [20]
Efavirenz DMC0GSJ Moderate Increased risk of hepatotoxicity by the combination of Sulfisoxazole and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [21]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Sulfisoxazole and Mipomersen. Hyper-lipoproteinaemia [5C80] [22]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Sulfisoxazole and BMS-201038. Hyper-lipoproteinaemia [5C80] [23]
Methotrexate DM2TEOL Moderate Increased plasma concentration of Sulfisoxazole and Methotrexate due to competitive binding of plasma proteins. Leukaemia [2A60-2B33] [24]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Sulfisoxazole and Porfimer Sodium. Lung cancer [2C25] [25]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Sulfisoxazole and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [26]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Sulfisoxazole and Idelalisib. Mature B-cell leukaemia [2A82] [27]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Sulfisoxazole and Clofarabine. Mature B-cell lymphoma [2A85] [28]
Methoxsalen DME8FZ9 Moderate Increased risk of photosensitivity reactions by the combination of Sulfisoxazole and Methoxsalen. Mycosis fungoides [2B01] [11]
Prilocaine DMI7DZ2 Major Increased risk of methemoglobinemia by the combination of Sulfisoxazole and Prilocaine. Pain [MG30-MG3Z] [29]
Verteporfin DMIY6DB Moderate Increased risk of photosensitivity reactions by the combination of Sulfisoxazole and Verteporfin. Psoriasis [EA90] [19]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Sulfisoxazole and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [19]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Sulfisoxazole and Naltrexone. Substance abuse [6C40] [30]
Warfarin DMJYCVW Major Decreased metabolism of Sulfisoxazole caused by Warfarin mediated inhibition of CYP450 enzyme. Supraventricular tachyarrhythmia [BC81] [31]
Tolbutamide DM02AWV Moderate Increased risk of hypoglycemia by the combination of Sulfisoxazole and Tolbutamide. Type 2 diabetes mellitus [5A11] [13]
Chlorpropamide DMPHZQE Moderate Increased risk of hypoglycemia by the combination of Sulfisoxazole and Chlorpropamide. Type 2 diabetes mellitus [5A11] [13]
Insulin-detemir DMOA4VW Moderate Increased risk of hypoglycemia by the combination of Sulfisoxazole and Insulin-detemir. Type-1/2 diabete [5A10-5A11] [12]
Insulin degludec DMPL395 Moderate Increased risk of hypoglycemia by the combination of Sulfisoxazole and Insulin degludec. Type-1/2 diabete [5A10-5A11] [12]
⏷ Show the Full List of 33 DDI Information of This Drug

References

1 Sulfisoxazole FDA Label
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 BDDCS applied to over 900 drugs
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs. Antimicrob Agents Chemother. 1995 Aug;39(8):1756-63.
8 Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments. Drug Metab Dispos. 2000 Apr;28(4):475-81.
9 A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metab Dispos. 2008 Aug;36(8):1689-97.
10 Assessment of the inhibitory effects and molecular docking of some sulfonamides on human serum paraoxonase 1. J Biochem Mol Toxicol. 2017 Oct;31(10).
11 Cerner Multum, Inc. "Australian Product Information.".
12 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
13 Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301. [PMID: 14071924]
14 Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
15 Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
16 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
17 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
18 Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
19 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
20 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
21 Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
22 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
23 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
24 Bannwarth B, Pehourcq F, Schaeverbeke T, Dehais J "Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis." Clin Pharmacokinet 30 (1996): 194-210. [PMID: 8882301]
25 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
26 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
27 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
28 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
29 Canadian Pharmacists Association.
30 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
31 Cook DE, Ponte CD "Suspected trimethoprim sulfamethoxazole induced hypoprothrombinemia." J Fam Pract 39 (1994): 589-91. [PMID: 7798864]